Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Oncology · The big question

Healthy daily habits tied to lower mortality in cancer survivors

Adherence to 24-hour movement guidelines and mortality risks in US cancer survivors: a national cohort study.

Editorial illustration for Adherence to 24-hour movement guidelines and mortality risks in US cancer survivors: a national cohort study.
Editorial illustration

Summary

Doctors have long known that getting enough exercise, sitting less, and sleeping well are good for our health. But instead of looking at these habits one by one, researchers recently explored how they work together over a full 24-hour day. A national study looked at the daily routines of 2,551 cancer survivors in the United States to see how their overall movement and rest habits impacted their long-term survival.

The researchers measured whether the survivors met established guidelines for three specific daily behaviors: aerobic physical activity, limiting sedentary time, and getting enough sleep. The results were striking. Compared to patients who met none of these benchmarks, survivors who hit all three saw their overall risk of dying drop by 45 percent. Even more notably, their risk of dying specifically from cancer was reduced by nearly 80 percent.

Despite these strong benefits, maintaining all three habits is uncommon. The study found that only about 13 percent of the cancer survivors met all three guidelines, while 14 percent did not meet any. Researchers noted that these protective benefits were especially strong for survivors living with obesity. However, because this research relied on observational survey data, it can only show a link between these healthy habits and longer lives, rather than proving a definitive cause and effect.

Why it matters.

As medical treatments improve, the number of cancer survivors continues to grow. This research highlights an empowering message for this expanding population: daily lifestyle choices like going for a walk, standing up more often, and prioritizing a good night of sleep could play a massive role in extending their lives. By focusing on the whole 24-hour day rather than just a quick workout, patients have a broader roadmap for taking control of their health after overcoming cancer.

For healthcare providers, this data suggests that post-cancer care should emphasize a holistic approach to daily habits, particularly for patients who have obesity. Helping patients build better routines around sleep and movement might be one of the most accessible and affordable ways to improve long-term survival rates, giving patients actionable steps to protect their future health.

From the source

The story in numbers.

Cancer survivors included in the cohort
2,551
Hazard ratio for cancer-specific mortality (meeting 3 vs 0 guidelines)
0.22
Proportion of participants meeting all three guidelines
12.6%
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗